<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F256203D-A286-46E9-B7B9-CE0809D3C14F"><gtr:id>F256203D-A286-46E9-B7B9-CE0809D3C14F</gtr:id><gtr:name>Leeds General Infirmary</gtr:name><gtr:address><gtr:line1>Great George Street</gtr:line1><gtr:city>LEEDS</gtr:city><gtr:postCode>LS1 3EX</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E04B03B-DFD7-4B9D-B0D6-DE5941A0774A"><gtr:id>5E04B03B-DFD7-4B9D-B0D6-DE5941A0774A</gtr:id><gtr:name>European Society for Blood and Marrow Transplantation (EBMT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2D017FB7-303D-48E6-AAFF-06303F046804"><gtr:id>2D017FB7-303D-48E6-AAFF-06303F046804</gtr:id><gtr:name>Royal Marsden NHS Foundation Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6B75F236-A0CF-4625-A84A-0C0706188A57"><gtr:id>6B75F236-A0CF-4625-A84A-0C0706188A57</gtr:id><gtr:name>Heart of England NHS Foundation Trust</gtr:name><gtr:department>Clinical Haematology</gtr:department><gtr:address><gtr:line1>Birmingham Heartlands Hospital</gtr:line1><gtr:line2>Bordesley Green East</gtr:line2><gtr:line4>Birmingham</gtr:line4><gtr:postCode>B9 5SS</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6B75F236-A0CF-4625-A84A-0C0706188A57"><gtr:id>6B75F236-A0CF-4625-A84A-0C0706188A57</gtr:id><gtr:name>Heart of England NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Birmingham Heartlands Hospital</gtr:line1><gtr:line2>Bordesley Green East</gtr:line2><gtr:line4>Birmingham</gtr:line4><gtr:postCode>B9 5SS</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F256203D-A286-46E9-B7B9-CE0809D3C14F"><gtr:id>F256203D-A286-46E9-B7B9-CE0809D3C14F</gtr:id><gtr:name>Leeds General Infirmary</gtr:name><gtr:address><gtr:line1>Great George Street</gtr:line1><gtr:city>LEEDS</gtr:city><gtr:postCode>LS1 3EX</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E04B03B-DFD7-4B9D-B0D6-DE5941A0774A"><gtr:id>5E04B03B-DFD7-4B9D-B0D6-DE5941A0774A</gtr:id><gtr:name>European Society for Blood and Marrow Transplantation (EBMT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2D017FB7-303D-48E6-AAFF-06303F046804"><gtr:id>2D017FB7-303D-48E6-AAFF-06303F046804</gtr:id><gtr:name>Royal Marsden NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/741F6676-8B0D-49D5-9EA0-4D5FF967EFFE"><gtr:id>741F6676-8B0D-49D5-9EA0-4D5FF967EFFE</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:surname>Catovsky</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/508287B4-A0EA-4B9E-AEC9-85B905AAAD03"><gtr:id>508287B4-A0EA-4B9E-AEC9-85B905AAAD03</gtr:id><gtr:firstName>Donald</gtr:firstName><gtr:otherNames>W</gtr:otherNames><gtr:surname>Milligan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0001160"><gtr:id>A0562A26-53A3-4F1A-9F98-B963446EB78E</gtr:id><gtr:title>The value of autografting in patients (AGED 15-65) with high risk chronic lymphoncytic leukemia (CLL) A randomised phas</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0001160</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2008-01-16</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-01-17</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>182686</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Marsden NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC CLL Pilot Study of feasibility of peripheral blood stem cell transplantation in CLL</gtr:description><gtr:id>A5A7E0BB-46A0-400F-A6EA-2B0F35AA2579</gtr:id><gtr:impact>The results demonstrated that autografting in CLL is safe and effective however subsequent trials with antibody based therapy have shown equal efficacy at a lower cost. QOL analysis has shown that autografting results in an early diminution of QOL which takes months to improve. Overall the results have discouraged autografting as a standard of care in this condition with substantial healthcare savings. Since publication of the data the number of autografts for CLL in Europe and the US has fallen by &amp;gt;90%.</gtr:impact><gtr:outcomeId>ascDpcYNRaH-1</gtr:outcomeId><gtr:partnerContribution>MRC CLL V was analysed as part of a planned Intergroup trial with collaborative groups from France, Germany and Switzerland as well as the EBMT. The Royal Marsden Hospital NHS Trust collected the Quality of Life Data and the analysis was conducted by the EBMT Statistical centre at Leiden. Additional statistical support was provided by the CTSU at the University of Oxford. Leeds General Infirmary assisted with diagnostic elements.</gtr:partnerContribution><gtr:piContribution>The MRC CLL Pilot Study of feasibility of peripheral blood stem cell transplantation in CLL closed in 2004 and accrued 120 patients, making it the largest European study of autologous transplantation in this condition. Patients were entered by 40 physicians and transplanted in 8 transplant centres in the UK.

CLL V was subsequently funded in the UK by the MRC and was run an intergroup study throughout the EBMT. The study closed in 2012 and accrued 223 patients.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC CLL Pilot Study of feasibility of peripheral blood stem cell transplantation in CLL</gtr:description><gtr:id>EB978FC4-7B70-49F5-A55A-24050CC5DA35</gtr:id><gtr:impact>The results demonstrated that autografting in CLL is safe and effective however subsequent trials with antibody based therapy have shown equal efficacy at a lower cost. QOL analysis has shown that autografting results in an early diminution of QOL which takes months to improve. Overall the results have discouraged autografting as a standard of care in this condition with substantial healthcare savings. Since publication of the data the number of autografts for CLL in Europe and the US has fallen by &amp;gt;90%.</gtr:impact><gtr:outcomeId>ascDpcYNRaH-2</gtr:outcomeId><gtr:partnerContribution>MRC CLL V was analysed as part of a planned Intergroup trial with collaborative groups from France, Germany and Switzerland as well as the EBMT. The Royal Marsden Hospital NHS Trust collected the Quality of Life Data and the analysis was conducted by the EBMT Statistical centre at Leiden. Additional statistical support was provided by the CTSU at the University of Oxford. Leeds General Infirmary assisted with diagnostic elements.</gtr:partnerContribution><gtr:piContribution>The MRC CLL Pilot Study of feasibility of peripheral blood stem cell transplantation in CLL closed in 2004 and accrued 120 patients, making it the largest European study of autologous transplantation in this condition. Patients were entered by 40 physicians and transplanted in 8 transplant centres in the UK.

CLL V was subsequently funded in the UK by the MRC and was run an intergroup study throughout the EBMT. The study closed in 2012 and accrued 223 patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leeds General Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC CLL Pilot Study of feasibility of peripheral blood stem cell transplantation in CLL</gtr:description><gtr:id>EDB3720F-9FE1-476A-BB66-B7E1822B0B09</gtr:id><gtr:impact>The results demonstrated that autografting in CLL is safe and effective however subsequent trials with antibody based therapy have shown equal efficacy at a lower cost. QOL analysis has shown that autografting results in an early diminution of QOL which takes months to improve. Overall the results have discouraged autografting as a standard of care in this condition with substantial healthcare savings. Since publication of the data the number of autografts for CLL in Europe and the US has fallen by &amp;gt;90%.</gtr:impact><gtr:outcomeId>ascDpcYNRaH-3</gtr:outcomeId><gtr:partnerContribution>MRC CLL V was analysed as part of a planned Intergroup trial with collaborative groups from France, Germany and Switzerland as well as the EBMT. The Royal Marsden Hospital NHS Trust collected the Quality of Life Data and the analysis was conducted by the EBMT Statistical centre at Leiden. Additional statistical support was provided by the CTSU at the University of Oxford. Leeds General Infirmary assisted with diagnostic elements.</gtr:partnerContribution><gtr:piContribution>The MRC CLL Pilot Study of feasibility of peripheral blood stem cell transplantation in CLL closed in 2004 and accrued 120 patients, making it the largest European study of autologous transplantation in this condition. Patients were entered by 40 physicians and transplanted in 8 transplant centres in the UK.

CLL V was subsequently funded in the UK by the MRC and was run an intergroup study throughout the EBMT. The study closed in 2012 and accrued 223 patients.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Society for Blood and Marrow Transplantation (EBMT)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>MRC CLL Pilot Study of feasibility of peripheral blood stem cell transplantation in CLL</gtr:description><gtr:id>898B95F6-5160-4E74-8B9F-7AD3DA10719E</gtr:id><gtr:impact>The results demonstrated that autografting in CLL is safe and effective however subsequent trials with antibody based therapy have shown equal efficacy at a lower cost. QOL analysis has shown that autografting results in an early diminution of QOL which takes months to improve. Overall the results have discouraged autografting as a standard of care in this condition with substantial healthcare savings. Since publication of the data the number of autografts for CLL in Europe and the US has fallen by &amp;gt;90%.</gtr:impact><gtr:outcomeId>ascDpcYNRaH-4</gtr:outcomeId><gtr:partnerContribution>MRC CLL V was analysed as part of a planned Intergroup trial with collaborative groups from France, Germany and Switzerland as well as the EBMT. The Royal Marsden Hospital NHS Trust collected the Quality of Life Data and the analysis was conducted by the EBMT Statistical centre at Leiden. Additional statistical support was provided by the CTSU at the University of Oxford. Leeds General Infirmary assisted with diagnostic elements.</gtr:partnerContribution><gtr:piContribution>The MRC CLL Pilot Study of feasibility of peripheral blood stem cell transplantation in CLL closed in 2004 and accrued 120 patients, making it the largest European study of autologous transplantation in this condition. Patients were entered by 40 physicians and transplanted in 8 transplant centres in the UK.

CLL V was subsequently funded in the UK by the MRC and was run an intergroup study throughout the EBMT. The study closed in 2012 and accrued 223 patients.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Autografting in chronic lymphocytic leukaemia</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>BCSH Guidelines for the treatment of chronic lymphocytic leukaemia 2013</gtr:guidelineTitle><gtr:id>EB5380A6-EEAF-498C-9CCD-E834F9CB5B0B</gtr:id><gtr:impact>The trial results suggest that autografting may not be more effective than the current best practice of combined immuno-chemotherapy. This has implication commissioners (less investment) and patients (less morbidity)</gtr:impact><gtr:outcomeId>YQoLAFVT6y1</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CA9D5DB4-AB56-4ABC-B5B2-A09E2864A82E</gtr:id><gtr:title>Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b898148762a06ec68e77f8c842d4a3c2"><gtr:id>b898148762a06ec68e77f8c842d4a3c2</gtr:id><gtr:otherNames>Milligan DW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>546de63da6c0a0.98525409</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD0509AE-015D-4F2C-9BD4-3C6BB8CE2D99</gtr:id><gtr:title>Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study.</gtr:title><gtr:parentPublicationTitle>American journal of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb6201ce630ddbf97f4fa2f029863c8"><gtr:id>ccb6201ce630ddbf97f4fa2f029863c8</gtr:id><gtr:otherNames>de Wreede LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0361-8609</gtr:issn><gtr:outcomeId>547ec253380705.61321089</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5D6E116-B41D-416A-B2E1-63913FD5AA8B</gtr:id><gtr:title>Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80c0ed2da7957ef3258d64d0e6a93c5e"><gtr:id>80c0ed2da7957ef3258d64d0e6a93c5e</gtr:id><gtr:otherNames>Michallet M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>baSsa5HWr5E</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0001160</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>